Mortality due to colorectal cancer (CRC) is high and is associated with the development of liver metastases. Approximately 40% of human CRCs harbor an activating mutation in the KRAS oncogene. Tumor cells with activated KRAS are particularly sensitive to Reovirus T3D, a non-pathogenic oncolytic virus. The efficacy of virus-based therapies may be positively or negatively modulated by the host immune system. This study was designed to assess the effect of immunosuppression on Reovirus T3D oncolysis of established colorectal micrometastases in the liver. Mouse C26 CRC cells harbor a mutant Kras gene and are susceptible to Krasdependent oncolysis by Reovirus T3D in vitro. Isolated C26 liver tumors were established in syngenic immunocompetent BALB/c mice by intrahepatic injection. Reovirus T3D therapy was given as a single intratumoral injection in control mice and in cyclosporin A-treated immunosuppressed mice. Tumor growth was analyzed over time by non-invasive bioluminescence imaging. The outgrowth of established CRC liver metastases in immunocompetent mice was efficiently but temporarily inhibited with a single injection of Reovirus T3D. Immunosuppression with cyclosporin A markedly increased and prolonged the therapeutic effect and allowed complete Reovirus T3D-induced tumor eradication in a subpopulation of the mice. We conclude that Reovirus T3D is an effective therapeutic agent against established C26 colorectal liver metastases and that immunosuppression enhances treatment efficacy.
Introduction
Colorectal carcinoma (CRC) is the second most common cancer in the western world. Despite multiple therapeutic options, mortality is still high and is mainly due to the consequences of metastatic tumor growth in the liver. Therefore, effective novel therapeutics are urgently needed. The idea to use viruses as tumoricidal agents is relatively old, but clinical applications have been limited. Renewed interest was sparked by the finding that genetic defects within tumor cells can allow viruses to preferentially kill tumor cells over normal cells. 1 Reovirus T3D is a double-stranded RNA-containing virus that belongs to the Reoviridae family. 2 Reovirus T3D specifically kills (tumor) cells with activated RAS which may facilitate virus replication and stimulates virus-induced tumor cell apoptosis. [2] [3] [4] As approximately 40% of human CRCs harbor an activating mutation in the KRAS oncogene, 5 Reovirus T3D may be an attractive therapeutic agent against (metastatic) CRC. Reovirus has an excellent safety profile as infections in adults usually occur asymptomatically. Recently, several animal studies have demonstrated the efficacy of reovirus as an oncolytic agent for colon and ovarian tumors, intracranial gliomas, breast cancer and lymphoid malignancies. 1, 6 Reovirus therapy in non-human primates is safe and well tolerated. 6 Furthermore, a phase I study demonstrated that reovirus therapy in patients with cutaneous metastases from systemic cancer was safe and several tumor responses were recorded. 7 When using oncolytic viruses in immunocompetent hosts, the role of the host immune system has to be taken into consideration. Immune-mediated virus clearance may reduce the therapeutic response. Indeed, immunosuppression by cyclosporin A or by T-cell depletion improved systemic reovirus therapy of experimental lung metastases in mice and prolonged survival. 8 Conversely, viral infection of established tumors may also lead to the generation of an anti-tumor immune response and to increased tumor clearance. 1 In addition, reovirus infections produce a robust inflammatory response in the liver 2 which may affect the therapeutic anti-tumor response.
Here we have analyzed the efficacy of Reovirus T3D as an oncolytic agent against colorectal metastases in the liver and we assessed how immunosuppression affected the therapeutic response.
Materials and methods

Cell lines and culture conditions
The murine colon carcinoma cell line C26 was obtained from the American Type Tissue Culture Collection (ATCC, Rockville, MD). C26 cells expressing the firefly luciferase gene (C26-luc) were described previously. 9 Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Dulbecco, ICN Pharmaceuticals, Costa Mesa, CA) supplemented with 5% (v/v) fetal calf serum, 2 mM glutamine, 0.1 mg ml À1 streptomycin, and 100 U ml
À1
penicillin. All cells were kept at 371C in a humidified atmosphere containing 5% CO 2 .
In vivo experiments Isolated liver metastases were induced in BALB/c mice by injecting 10 5 C26-luc cells in 50 ml PBS into the parenchyma of the left liver lobe. Twenty-four hours after injection of tumor cells, the liver was exteriorized and at the exact sites of identifiable tumor growth, the tumor-bearing liver lobe was injected with 10 11 PFU reovirus in 50 ml PBS or PBS alone as a control, and the abdomen was closed (n ¼ 9/group without CyA, n ¼ 16/ group with CyA). All experiments were performed in accordance with the guidelines of the University's Animal Experimental Committee, University Medical Center Utrecht, The Netherlands.
Bioluminescence imaging (BLI)
Tumor outgrowth was measured non-invasively by bioluminescence imaging (BLI), exactly as described previously . 9 In brief, on days 5, 7, 9, 11 and 13 after tumor cell injection, hepatic tumor growth was assessed by in vivo BLI with a highly sensitive, cooled chargecoupled device (CCCD) camera (VersArray 1300B, Roper Scientific Inc., Vianen, The Netherlands) mounted in a light-tight imaging chamber (Roper Scientific Inc., Vianen, The Netherlands). Before imaging, mice were anesthetized and the substrate D-luciferin sodium salt (Synchem Laborgemeinschaft OHG, Kassel, Germany) dissolved in PBS was injected i.p. at a dose of 125 mg kg
À1
. All mice were imaged with an integration time of 5 min, exactly 10 min after the i.p. injection of D-luciferin. Imaging and quantification of signals were controlled by the acquisition software MetaVue (Universal Imaging Corporation, Downingtown, PA). Total photon counts were quantified with MetaMorph software.
Immunosuppression
The host immune system was suppressed preoperatively and during the course of the experiment by i.p. injections of cyclosporin A (Novartis, Arnhem, The Netherlands) at 50 mg kg À1 on pod À2, 0, 2, 4, 6, 8, 10 and 12.
Statistical analyses
Differences between the groups were statistically evaluated using the Mann-Whitney test. Results are presented as means7s.e. All P-values were two tailed. Po0.05 was considered statistically significant.
Results and Discussion
Reovirus T3D selectively kills tumor cells with an activated Ras pathway. 3 This has raised considerable interest in using Reovirus T3D as an oncolytic agent in the treatment of a variety of tumor types both in preclinical and in clinical studies. C26 is an aggressive colorectal cancer (CRC) cell line that contains constitutively activated Kras owing to an activating point mutation in codon 12 (G12D). 4 We have recently shown that knockdown of Kras D12 by RNA interference prevented apoptosis induction by Reovirus T3D. 4 Therefore, we chose to assess the therapeutic effect of Reovirus T3D on the outgrowth of pre-established C26 liver tumors.
Liver tumors were induced by direct intrahepatic injection of 10 5 C26 cells. After 24 h the abdomen was re-opened and small macroscopic lesions (approximately 1 mm in diameter) were visible in all mice. Reovirus (10 11 PFU) was injected directly into the liver, at the sites of these lesions.
Injection of Reovirus T3D strongly inhibited tumor growth (by 76%) 5 days after tumor induction, when compared to injection of PBS (P ¼ 0.07). However, the anti-tumor effect rapidly diminished from day 7 onwards to only 11% inhibition on day 13 (Figure 1a and b) . We hypothesized that the decreased anti-tumor effect was due to an anti-viral immune response raised by the immunocompetent hosts. Therefore, the mice were (pre)treated with intraperitoneal injections of cyclosporin A (CyA; 50 mg kg À1 ) every second day, beginning 2 days before tumor cell injection. Again, tumor growth was strongly inhibited by Reovirus T3D when measured 5 days after tumor induction (by 77%). However, CyA treatment markedly enhanced and prolonged the therapeutic effect of Reovirus T3D: 11 and 13 days following tumor induction, tumor growth was still inhibited by 81 and 67%, respectively (Figure 1a and b) . Importantly, CyA treatment did not significantly affect tumor growth in control mice, which excludes a potential direct inhibitory effect of CyA on C26 tumor growth (Figure 1c) . Remarkably, Reovirus T3D therapy resulted in complete tumor regression in two CyA-treated mice (Figure 1d ). This was not observed in any of the mice in the Reovirus T3D-treated group without CyA nor in the control groups. In fact, we have never observed regression of C26 tumors in any of our previous studies using several chemo-and anti-angiogenic therapeutics. The only other therapy that completely cures mice of C26 liver tumors is local destruction of the liver tumor by laser coagulation, combined with chemotherapy (our unpublished results). Our finding that Reovirus T3D can cause regression of C26 liver tumors as a single treatment modality in immunosuppressed mice highlights its potential as an oncolytic agent. Immunosuppression increased and prolonged the anti-tumor effect of a single Reovirus T3D injection This is in line with the findings by Hirasawa et al. 8 who reported that immunosuppression increased the anti-tumor response after systemic application of reovirus. Conversely, immunosuppression had no effect on reovirus oncolysis of gliomas in a model in rats. 6 Reovirus therapy in immunocompromised SCID mice is associated with severe morbidity 10 but we have not observed this in the CyA-treated mice used in the present study. Apparently, CyA treatment sufficed to prevent Reovirus T3D clearance from the liver, without inducing a profound systemic infection and morbidity. Acceleration of tumor growth is a potential risk factor of immunosuppression for cancer patients. This was not observed in our experiments in mice. Whether immunosuppression is applicable and/or beneficiary in the treatment of cancer patients remains to be determined. Reovirus therapy of colorectal liver metastases N Smakman et al
